DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $5.6M
- Closes
- Sep 30, 2026 (in 15 days)
Similar opportunities open now
- DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Autism Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 37 days
- DoW Arthritis Clinical Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 37 days
Classification and identifiers
- Solicitation number
- HT942526ALSRPPCTA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $5.6M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award ...